研究

Vitolo U, Burgues JMB, Duell J, Kwiatek M, Belada D, Jurczak W, Maerevoet M, Sibon D, Greil R, Kumode T, López-Jimenez J, Meert C, Cia JS, Thieblemont C, Alcaide SO, Kim WS, Cordoba R, Wielgos-Bonvallet M, Jiang T, Wang Y, McGoldrick S, Guo E, Morschhauser F, Woei-A-Jin FJSH.

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

Kumode T, Sawa H, Miyawaki K, Satake A, Kanemura N, Suzuki R, Fujiwara Y, Nagate Y, Ota S, Fujino T, Goto H, Fukuhara N, Sakata-Yanagimoto M, Izutsu K, Nishikori M, Shibayama H, Ennishi D, Shimose T, Asai M, Matsumura I, Akashi K, Kato K.

Real-World Safety and Efficacy of Pola-R-CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients.

Aoki T, Duns G, Rai S(co-1st), Jiang A, Lytle A, Yin Y, Kishida M, Yu Li M, Lee C, Smorra D, Hilton LK, Healy S, Alig SK, Shahrokh Esfahani M, Sarkozy C, Hung SS, Milne K, Telenius A, O Brien L, Wong JC, Cassidy C, Fujisawa M, Strong C, Goodyear T, Di Vito C, Luksik C, Edin G, Gonzalez L, Rangel Patiño J, Hong M, Wu S, Lee E, Sakhdari A, Takata K, Miyata-Takata T, Boyle M, Ben-Neriah S, Weng AP, Xu A, Merchant A, Roth A, Crump M, Kuruvilla J, Prica A, Kridel R, Huntsman DG, Nelson BH, Farinha P, Morin RD, Alizadeh AA, Savage KJ, Scott DW, Steidl C.

Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.

Haeno T, Sakai K, Minamoto S, Nakatsu D, De Velasco MA, Rai S, Tanaka H, Matsumura I, Nishio K.

Clonal Complexity Defines Distinct Tumor-Intrinsic Biology and Prognosis in Diffuse Large B-Cell Lymphoma.

Sehn LH, Hübel K, Luminari S, Scholz CW, Salar A, Paneesha S, Wahlin BE, Panayiotidis P, Lee HP, Jiménez-Ubieto A, Sancho JM, Kim TM, Domingo Domenech E, Kumode T, Poh C, Thieblemont C, Deeren D, de Wit E, Arbushites M, Vassallo I, Trneny M.

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial

Rai S, Duns G, Frontzek F, Wong JCH, Yin Y, Li MY, Kishida M, Fujisawa M, Healy S, Viganò E, Jiang A, Woolcock B, Telenius A, Ben-Neriah S, Meissner B, Boyle M, Nakamura H, O Brien L, Cassidy C, Lytle A, Farinha P, Slack GW, Hilton LK, Morin RD, Venturutti L, Aoki T, Wretham N, Bush JW, Evgin L, Savage KJ, Scott DW, Steidl C.

Somatic IRF4 Mutations and Thymic Tropism in Primary Mediastinal Large B-cell Lymphoma

Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, Yokoyama M, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Shibayama H, Uchida T, Yang DH, Ishitsuka K, Ishizawa K, Kim JS, Lee HG, Minami H, Eom HS, Kurosawa M, Lee JH, Lee JS, Lee WS, Nagai H, Shindo T, Yoon DH, Yoshida S, Gillings M, Onogi H, Tobinai K.

Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results

Alig SK, Shahrokh Esfahani M, Garofalo A, Li MY, Rossi C, Flerlage T, Flerlage JE, Adams R, Binkley MS, Shukla N, Jin MC, Olsen M, Telenius A, Mutter JA, Schroers-Martin JG, Sworder BJ, Rai S, King DA, Schultz A, Bögeholz J, Su S, Kathuria KR, Liu CL, Kang X, Strohband MJ, Langfitt D, Pobre-Piza KF, Surman S, Tian F, Spina V, Tousseyn T, Buedts L, Hoppe R, Natkunam Y, Fornecker LM, Castellino SM, Advani R, Rossi D, Lynch R, Ghesquières H, Casasnovas O, Kurtz DM, Marks LJ, Link MP, André M, Vandenberghe P, Steidl C, Diehn M, Alizadeh AA.

Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling

Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G.

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

Rai S, Tanaka H, Suzuki M, Espinoza JL, Kumode T, Tanimura A, Yokota T, Oritani K, Watanabe T, Kanakura Y, Matsumura I.

Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V.

Nawaz W, Fong A, Cardoso MP, Tang J, Zhao J, Li MY, Rai S, Beresford A, Alduaij W, Boyle M, Steidl C, Scott DW, Venturutti L.

Non-canonical NF-κB drives a fate switch from germinal center to early effector B cells

Izutsu K, Fujimoto A, Rai S, Maruyama D, Ohmachi K, Yokohama A, Tsukasaki K, Uchida T, Kuroda J, Choi I, Hidaka M, Ando J, Sakamoto T, Kato H, Minami H, Yoshida S, Yamamoto M, Gillings M, Onogi H, Takeuchi K.

TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial.

Makita S, Izutsu K, Mishima Y, Kumode T, Kuroda J, Kanemura N, Fukuhara N, Shimada K, Mori C, Kawasaki A, Miyake T, Maruyama D.

Efficacy and safety of subcutaneous mosunetuzumab in combination with lenalidomide and as a monotherapy in Japanese patients with relapsed/refractory follicular lymphoma.

Onozawa M, Kusumoto S, Kuwatsuka Y, Miyazono T, Tanaka M, Najima Y, Okada K, Shiratori S, Sato T, Kanda J, Inagaki Y, Murayama T, Hatano K, Onodera K, Sakurai M, Endo S, Kumode T, Itonaga H, Moriuchi Y, Kanemura N, Imi T, Edahiro T, Fukushima N, Oura M, Yui S, Watanabe M, Toubai T, Ando T, Nakamura D, Tamaki M, Kakinoki Y, Okada T, Nakano N, Tachibana T, Shimizu H, Ota S, Iida S, Sugiyama M, Atsuta Y, Teshima T, Yoshizumi T, Mizokami M.

Vaccine-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial.

Yin Y, Rai S(co-1st), Jiang A, Xu A, O'Brien L, Telenius A, Delabie J, Chong L, Hung S, Merchant A, Scott DW, Savage KJ, Aoki T, Steidl C.

Tumor microenvironment differences between diagnostic and relapsed classic Hodgkin lymphoma revealed by scRNA-seq

Takenaka K, Ito T, Komatsu N, Yamaguchi H, Kirito K, Tomita A, Togano T, Tanaka T, Sugimoto Y, Murai K, Wada H, Kurokawa T, Koike M, Gotoh A, Maekawa T, Kubuki Y, Akagi T, Yamauchi T, Edahiro Y, Ikeda K, Kondo T, Tanaka H, Miyazaki Y, Saito TI, Shimoda K, Kada A, Saito AM, Kiyoi H, Akashi K, Matsumura I, Takaori A.

Prospective observational study to assess the prognosis of patients with myeloproliferative neoplasms in Japan (MPN-15): results of baseline analysis.

Izutsu K, Akahane D, Toubai T, Saito T, Mishima Y, Fujisaki T, Nishikori M, Kumode T, Suehiro Y, Ishitsuka K, Patah P, Takahashi A, Månsson BD, Favaro E, Fukuhara N.

Three-year follow-up of epcoritamab therapy in Japanese patients with relapsed/refractory follicular lymphoma in EPCORE NHL-3.

Nakamura F, Ishiyama K, Suzuki R, Maruyama H, Onishi Y, Usuki K, Koh H, Takenaka K, Saiki R, Ogawa S, Matsumoto K, Takahashi T, Hosomichi K, Zaimoku Y, Yoshimura K, Matsumura I, Akashi K, Nakao S.

Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion-dependent aplastic anaemia: West Japan Hematology Study Group (W-JHS) AA02 trial.

Falchi L, Nijland M, Huang H, Linton KM, Seymour JF, Tao R, Kwiatek M, Costa A, Vassilakopoulos TP, Greil R, Jiménez-Ubieto A, Gangatharan SA, Benjamini O, Thieblemont C, Tucci A, Elinder-Camburn A, Illes A, Novak J, Pavlovsky MA, McDonald A, Yoon DH, Maruyama D, Sunkersett G, Mei JP, Mukherjee N, Zhu F, Alshreef A, Favaro E, Morschhauser F.

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial

Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trněný M, Lenz G, Sharman JP, Herbaux C, Burke JM, Matasar M, Collins GP, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Pinto A, Rai S, Izutsu K, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Jiang Y, McCall B, Chohan S, Sugidono M, Yan M, Lee Batlevi C, Tilly H, Flowers CR.

Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma

Izutsu K, Watanabe M, Toubai T, Tsukamoto T, Maruyama D, Kumode T, Fukuhara N, Ogawa N, Satomi N, Nishimura Y, Honda H, Chyla B, Takizawa J.

Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study

Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, Kurahashi S, Ueda Y, Dobashi N, Maeda T, Matsumura I, Tanaka M, Kako S, Ichinohe T, Fukuda T, Ohtake S, Ishikawa Y, Miyazaki Y, Sakaida E, Maeda Y, Yamauchi T, Kiyoi H.

Dasatinib is superior to imatinib in adult Ph + ALL: a propensity score-matched analysis of pooled JALSG trial data

Suzuki T, Jo T, Yoshifuji K, Kondo T, Doki N, Kanda Y, Nishida T, Onishi Y, Asada N, Fukuda T, Sawa M, Hasegawa Y, Serizawa K, Ota S, Tanaka M, Yoshimitsu M, Atsuta Y, Kanda J.

Impact of methotrexate-dosing regimens for GVHD prophylaxis on clinical outcomes of HLA-matched allogeneic HSCT.

Ishiyama K, Yamazaki M, Maruyama H, Hosono N, Yamaguchi H, Asada N, Tanimoto K, Sugiura H, Usuki K, Yoshimura K, Ogawa S, Kanakura Y, Matsumura I, Akashi K, Nakao S.

Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study

Yuji Nozaki, Koichi Murata, Akira Onishi, Kohei Tsujimoto, Wataru Yamamoto, Hirotaka Yamada, Sho Sendo, Motomu Hashimoto, Tadashi Okano, Hideyuki Shiba, Yuri Hiramatsu, Yonsu Son, Naofumi Yoshida, Rika Fukuda, Yumi Morimoto, Kazuya Kishimoto, Tetsu Itami, Daisuke Tomita, Chisato Ashida, Toshihiko Shiga, Koji Kinoshita

Clinical efficacy of JAK inhibitors for RA patients with poor-prognosis factors: the ANSWER cohort study

Yuji Nozaki, Toshihiko Shiga, Jinhai Ri, Tetsu Itami, Daisuke Tomita, Hirotaka Yamazawa, Yumi Morimoto, Rika Fukuda, Takashi Tsuchimoto, Sayo Morita, Hiroki Akazawa, Koichi Murata, Akira Onishi, Kosuke Ebina, Iku Shirasugi, Hirotaka Yamada, Motomu Hashimoto, Ryu Watanabe, Yumiko Wada, Tohru Takeuchi, Hideki Amuro, Akihiro Tanaka, Masaki Katayama, Yuki Etani, Wataru Yamamoto, Koji Kinoshita, Shinya Rai

Reduced versus standard dosing of Janus kinase inhibitors in rheumatoid arthritis: a propensity score–matched real-world study accounting for poor prognostic factors

Yuji Nozaki, Atsuhiro Yamamoto, Daisuke Tomita, Tomoko Hyodo, Hayato Kaida, Kazunari Ishii, Koji Kinoshita

Exploratory comparison of diffusion-weighted whole-body imaging with background body signal suppression and 18F-FDG PET/CT for assessing disease activity in large-vessel vasculitis